<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioScreening.net &#187; New Drugs</title>
	<atom:link href="http://www.bioscreening.net/category/news/new-drugs/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.bioscreening.net</link>
	<description>BioScreening news and events</description>
	<lastBuildDate>Thu, 29 Dec 2011 08:21:20 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3</generator>
		<item>
		<title>Research at A&amp;M and Scripps finds HIV-killing compound</title>
		<link>http://www.bioscreening.net/2011/11/28/research-at-am-and-scripps-finds-hiv-killing-compound/</link>
		<comments>http://www.bioscreening.net/2011/11/28/research-at-am-and-scripps-finds-hiv-killing-compound/#comments</comments>
		<pubDate>Mon, 28 Nov 2011 17:35:28 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[DNA Reasearch]]></category>
		<category><![CDATA[HIV Research]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[Research Projects]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1348</guid>
		<description><![CDATA[COLLEGE STATION - A powerful topical preventative for HIV, the virus that causes AIDS, could be a step closer to clinical trials, thanks to a newly discovered molecular compound that research at Texas A&#38;M University and the Scripps Research Institute shows dissolves the virus on contact. The ability of the synthetic compound known as &#8220;PD 404,182&#8243; [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/11/28/research-at-am-and-scripps-finds-hiv-killing-compound/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>First Clinical Trial of Autologous Cardiac Stem Cells Shows Positive Results</title>
		<link>http://www.bioscreening.net/2011/11/22/first-clinical-trial-of-autologous-cardiac-stem-cells-shows-positive-results-2/</link>
		<comments>http://www.bioscreening.net/2011/11/22/first-clinical-trial-of-autologous-cardiac-stem-cells-shows-positive-results-2/#comments</comments>
		<pubDate>Tue, 22 Nov 2011 19:13:28 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Genetics & Pharmacogenetics]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[Research Projects]]></category>
		<category><![CDATA[Stem Cell Research]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1345</guid>
		<description><![CDATA[Initial data from the first ever trial to evaluate autologous cardiac stem cell (CSC) transplants in humans suggests that the treatment improves left ventricular (LV) systolic function by an average of 12% over one year, and reduces infarct size in patients with severe heart failure due to ischemic heart disease. The trial investigators say the results triple the 4% [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/11/22/first-clinical-trial-of-autologous-cardiac-stem-cells-shows-positive-results-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vaccine for ovarian, breast cancer shows promise</title>
		<link>http://www.bioscreening.net/2011/11/09/vaccine-for-ovarian-breast-cancer-shows-promise/</link>
		<comments>http://www.bioscreening.net/2011/11/09/vaccine-for-ovarian-breast-cancer-shows-promise/#comments</comments>
		<pubDate>Wed, 09 Nov 2011 18:40:50 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1312</guid>
		<description><![CDATA[(CBS) A new vaccine that targets ovarian and breast cancer has shown promise in early studies, giving scientists hope they may be closer to stopping the deadly diseases. PICTURES: 25 breast cancer myths busted Known as PANVAC, the vaccine triggers the immune system to attack tumor cells. &#8220;With this vaccine, we can clearly generate immune [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/11/09/vaccine-for-ovarian-breast-cancer-shows-promise/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Body &amp; Mind &#8211; HEALTH U.S. Doctor Cautious About HIV Vaccine</title>
		<link>http://www.bioscreening.net/2011/09/29/body-mind-health-u-s-doctor-cautious-about-hiv-vaccine/</link>
		<comments>http://www.bioscreening.net/2011/09/29/body-mind-health-u-s-doctor-cautious-about-hiv-vaccine/#comments</comments>
		<pubDate>Thu, 29 Sep 2011 19:36:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[HIV Research]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1299</guid>
		<description><![CDATA[A New York City-based infectious disease specialist said a new vaccine developed by Spanish scientists, which could turn HIV into minor infection status, is reason to be cautiously optimistic. Dr. Joseph Rahimian said Thursday news of an HIV vaccine is certainly exciting, but questions remain. “An HIV vaccine has been the holy grail for infectious [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/09/29/body-mind-health-u-s-doctor-cautious-about-hiv-vaccine/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>7TH DUESSELDORF SYMPOSIUM ON IMMUNOTOXICOLOGY Biology of the Arylhydrocarbon Receptor</title>
		<link>http://www.bioscreening.net/2011/09/13/7th-duesseldorf-symposium-on-immunotoxicology-biology-of-the-arylhydrocarbon-receptor/</link>
		<comments>http://www.bioscreening.net/2011/09/13/7th-duesseldorf-symposium-on-immunotoxicology-biology-of-the-arylhydrocarbon-receptor/#comments</comments>
		<pubDate>Tue, 13 Sep 2011 16:27:15 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Targeted Libraries]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1285</guid>
		<description><![CDATA[Heinrich Heine University Duesseldorf September 21 &#8211; 24, 2011 AhR research has taken great momentum recently, with a number of seminal discoveries, especially regarding its role in physiological events. This has opened new arenas, attracted new groups into the field, and led to a steep interest in the potential of AhR as a therapeutic target [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/09/13/7th-duesseldorf-symposium-on-immunotoxicology-biology-of-the-arylhydrocarbon-receptor/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Positive agreement received for approval of AXANUM (low-dose ASA/esomeprazole) in Europe</title>
		<link>http://www.bioscreening.net/2011/08/02/positive-agreement-received-for-approval-of-axanum-low-dose-asaesomeprazole-in-europe/</link>
		<comments>http://www.bioscreening.net/2011/08/02/positive-agreement-received-for-approval-of-axanum-low-dose-asaesomeprazole-in-europe/#comments</comments>
		<pubDate>Tue, 02 Aug 2011 17:50:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[R & D]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1229</guid>
		<description><![CDATA[AstraZeneca today announced that AXANUM, a fixed dose combination of 81 mg low-dose ASA (acetylsalicylic acid) and 20 mg esomeprazole, has received positive agreement for approval in 23 European Union member countries and in Norway. AXANUM is indicated for prevention of cardiovascular (CV) events such as heart attack or stroke, in high-risk CV patients in [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/08/02/positive-agreement-received-for-approval-of-axanum-low-dose-asaesomeprazole-in-europe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Daily pill can prevent HIV infection</title>
		<link>http://www.bioscreening.net/2011/07/14/daily-pill-can-prevent-hiv-infection/</link>
		<comments>http://www.bioscreening.net/2011/07/14/daily-pill-can-prevent-hiv-infection/#comments</comments>
		<pubDate>Thu, 14 Jul 2011 15:36:10 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Antibiotics]]></category>
		<category><![CDATA[Cell Analysis]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[HIV Research]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1211</guid>
		<description><![CDATA[The partners of people who have HIV can protect themselves from infection by taking a once-daily pill, two groundbreaking studies in Botswana, Kenya and Uganda have shown. The discovery could bring work to combat Aids close to a &#8220;tipping point&#8221;, experts say. Attempts to promote condom use to protect against HIV in the hardest-hit parts [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/07/14/daily-pill-can-prevent-hiv-infection/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Genentech to Appeal to F.D.A. for Breast Cancer Drug</title>
		<link>http://www.bioscreening.net/2011/06/27/genentech-to-appeal-to-f-d-a-for-breast-cancer-drug/</link>
		<comments>http://www.bioscreening.net/2011/06/27/genentech-to-appeal-to-f-d-a-for-breast-cancer-drug/#comments</comments>
		<pubDate>Mon, 27 Jun 2011 15:10:56 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Oncology Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1182</guid>
		<description><![CDATA[Genentech this week will step up its efforts to keep the drug Avastin available as a treatment for breast cancer, urging the Food and Drug Administration to give it one more chance to prove the medicine works. At a hearing on Tuesday and Wednesday in suburban Washington, Genentech will ask the F.D.A. to reconsider its [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/27/genentech-to-appeal-to-f-d-a-for-breast-cancer-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Kidney improvement sustained by Abbott drug-study</title>
		<link>http://www.bioscreening.net/2011/06/24/kidney-improvement-sustained-by-abbott-drug-study/</link>
		<comments>http://www.bioscreening.net/2011/06/24/kidney-improvement-sustained-by-abbott-drug-study/#comments</comments>
		<pubDate>Fri, 24 Jun 2011 15:18:36 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1177</guid>
		<description><![CDATA[NEW YORK, June 24 (Reuters) &#8211; Diabetics with moderate to severe chronic kidney disease showed significant and sustained improvement in kidney function through 52 weeks of treatment with a novel drug being developed by Abbott Laboratories (ABT.N), according to data from a midstage clinical trial. The oral drug, bardoxolone methyl, is the first medicine to [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/24/kidney-improvement-sustained-by-abbott-drug-study/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer&#8217;s Remoxy Fails to Win FDA Approval</title>
		<link>http://www.bioscreening.net/2011/06/24/pfizers-remoxy-fails-to-win-fda-approval/</link>
		<comments>http://www.bioscreening.net/2011/06/24/pfizers-remoxy-fails-to-win-fda-approval/#comments</comments>
		<pubDate>Fri, 24 Jun 2011 15:13:22 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[R & D]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1175</guid>
		<description><![CDATA[WASHINGTON &#8212; The latest attempt at an abuse-resistant formulation of oxycodone (Remoxy) failed to win approval from the FDA, according to a statement from Pfizer. Late Thursday, the company said it had received a complete response letter from the FDA, which described the reasons for the FDA&#8217;s decision. The FDA had turned down an earlier [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/24/pfizers-remoxy-fails-to-win-fda-approval/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Drug Effectively Treats Hepatitis C</title>
		<link>http://www.bioscreening.net/2011/06/23/new-drug-effectively-treats-hepatitis-c/</link>
		<comments>http://www.bioscreening.net/2011/06/23/new-drug-effectively-treats-hepatitis-c/#comments</comments>
		<pubDate>Thu, 23 Jun 2011 20:36:04 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[Hepatitis Research]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[R & D]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1172</guid>
		<description><![CDATA[WEDNESDAY, June 22 (HealthDay News) &#8212; The recently approved drug Incivek, combined with two standard drugs, is highly effective at treating hepatitis C, a notoriously difficult-to-manage liver disease, two new studies show. The drug works not only in patients just starting treatment, but in those who failed earlier treatment, the research found. The hepatitis C [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/23/new-drug-effectively-treats-hepatitis-c/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Safety Dooms Novel Staph Vaccine</title>
		<link>http://www.bioscreening.net/2011/06/08/safety-dooms-novel-staph-vaccine/</link>
		<comments>http://www.bioscreening.net/2011/06/08/safety-dooms-novel-staph-vaccine/#comments</comments>
		<pubDate>Wed, 08 Jun 2011 15:23:11 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[North America]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1142</guid>
		<description><![CDATA[A phase II/III trial of V710, an investigational vaccine for the prevention of Staphylococcus aureus infection, has been stopped for good following a risk-benefit analysis, according to Merck and Intercell AG. In April, the Data Monitoring Committee recommended suspending enrollment even though a pre-specified interim analysis showed that the trial did not meet futility criteria. [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/06/08/safety-dooms-novel-staph-vaccine/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Okays New HIV Drug</title>
		<link>http://www.bioscreening.net/2011/05/20/fda-okays-new-hiv-drug/</link>
		<comments>http://www.bioscreening.net/2011/05/20/fda-okays-new-hiv-drug/#comments</comments>
		<pubDate>Fri, 20 May 2011 17:56:02 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[FDA News]]></category>
		<category><![CDATA[HIV Research]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1108</guid>
		<description><![CDATA[WASHINGTON &#8212; The FDA has approved rilpivirine (Edurant) for the treatment of HIV patients who have not yet begun therapy. The drug, a non-nucleoside reverse transcriptase inhibitor, is intended to be used as part of highly active anti-retroviral therapy (HAART) with at least two other medications, the agency said. Rilpivirine, also known as TMC278, is [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/05/20/fda-okays-new-hiv-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UPDATE 1-US panel says Optimer&#8217;s antibiotic effective</title>
		<link>http://www.bioscreening.net/2011/04/05/update-1-us-panel-says-optimers-antibiotic-effective/</link>
		<comments>http://www.bioscreening.net/2011/04/05/update-1-us-panel-says-optimers-antibiotic-effective/#comments</comments>
		<pubDate>Tue, 05 Apr 2011 18:51:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[USA and Canada]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1086</guid>
		<description><![CDATA[Optimer Pharmaceuticals Inc&#8217;s (OPTR.O) experimental antibiotic is safe and effective in treating a bacterial infection that causes diarrhea, a U.S. advisory panel said on Tuesday. The advisory panel of 13 independent experts voted unanimously that the drug was effective but said there were concerns regarding the drug&#8217;s use in pregnant women and children. However, the [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/04/05/update-1-us-panel-says-optimers-antibiotic-effective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Higher bleeding risk seen in J&amp;J, Bayer clot drug</title>
		<link>http://www.bioscreening.net/2011/04/05/higher-bleeding-risk-seen-in-jj-bayer-clot-drug/</link>
		<comments>http://www.bioscreening.net/2011/04/05/higher-bleeding-risk-seen-in-jj-bayer-clot-drug/#comments</comments>
		<pubDate>Tue, 05 Apr 2011 18:44:59 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA News]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[New Products]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1084</guid>
		<description><![CDATA[A blood clot preventer from Johnson &#38; Johnson and Bayer caused a surprisingly high rate of bleeding in a trial of patients with acute illnesses, representing a significant setback for the drugmakers. Bayer AG shares fell 3.6 percent in Frankfurt on Tuesday. J&#38;J slid 0.6 percent on the New York Stock Exchange. Industry analysts had [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2011/04/05/higher-bleeding-risk-seen-in-jj-bayer-clot-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Trana Discovery&#8217;s HIV Assay Finds Compounds that Inhibit NNRTI and Multi-Drug Resistant HIV Viruses</title>
		<link>http://www.bioscreening.net/2010/12/15/trana-discoverys-hiv-assay-finds-compounds-that-inhibit-nnrti-and-multi-drug-resistant-hiv-viruses/</link>
		<comments>http://www.bioscreening.net/2010/12/15/trana-discoverys-hiv-assay-finds-compounds-that-inhibit-nnrti-and-multi-drug-resistant-hiv-viruses/#comments</comments>
		<pubDate>Wed, 15 Dec 2010 14:20:45 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[HIV Research]]></category>
		<category><![CDATA[New Drugs]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1055</guid>
		<description><![CDATA[Trana Discovery, Inc., an infectious disease drug discovery technology company, today announced that a recent study sponsored by the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health, affirms that bioactive compounds selected using the Trana HIV 201 High-Throughput (HTS) Assay inhibit viral strains demonstrating resistance to non-nucleoside reverse transcriptase [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/12/15/trana-discoverys-hiv-assay-finds-compounds-that-inhibit-nnrti-and-multi-drug-resistant-hiv-viruses/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Could Starfish Inspire New Cure for Inflammation?</title>
		<link>http://www.bioscreening.net/2010/12/13/could-starfish-inspire-new-cure-for-inflammation/</link>
		<comments>http://www.bioscreening.net/2010/12/13/could-starfish-inspire-new-cure-for-inflammation/#comments</comments>
		<pubDate>Mon, 13 Dec 2010 21:25:06 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Antibiotics]]></category>
		<category><![CDATA[Discoveries, Innovations and Patents]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[New Drugs]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/?p=1053</guid>
		<description><![CDATA[Lurking in the seas of Scotland is an unlikely candidate for a medical breakthrough. But scientists believe the starfish could hold the key to finding a new treatment for inflammatory conditions such as asthma, hay fever and arthritis. The species they are interested in is the spiny starfish (Marthasterias glacialis), and in particular the slimy [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/12/13/could-starfish-inspire-new-cure-for-inflammation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ion Channels Open Doors to New Drugs Increased R&amp;D Efforts Are Overcoming Obstacles and Showing Potential</title>
		<link>http://www.bioscreening.net/2010/07/08/ion-channels-open-doors-to-new-drugs-increased-rd-efforts-are-overcoming-obstacles-and-showing-potential/</link>
		<comments>http://www.bioscreening.net/2010/07/08/ion-channels-open-doors-to-new-drugs-increased-rd-efforts-are-overcoming-obstacles-and-showing-potential/#comments</comments>
		<pubDate>Thu, 08 Jul 2010 19:20:47 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[R & D]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/07/08/ion-channels-open-doors-to-new-drugs-increased-rd-efforts-are-overcoming-obstacles-and-showing-potential/</guid>
		<description><![CDATA[Nina Flanagan Ion channels make good drug targetsâ€”they reside on the cell surface and are fast switching mechanisms. They act like cell transistors, controlling many cell processes. There are close to 500 types of ion channels, yet many remain undiscovered. This was mainly attributed to technology restraints, however, with the recent introduction of HT patch [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/07/08/ion-channels-open-doors-to-new-drugs-increased-rd-efforts-are-overcoming-obstacles-and-showing-potential/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rising to the Challenge in R&amp;D</title>
		<link>http://www.bioscreening.net/2010/01/11/rising-to-the-challenge-in-rd/</link>
		<comments>http://www.bioscreening.net/2010/01/11/rising-to-the-challenge-in-rd/#comments</comments>
		<pubDate>Mon, 11 Jan 2010 21:22:54 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2010/01/11/rising-to-the-challenge-in-rd/</guid>
		<description><![CDATA[There has long been a consensus within the pharmaceutical industry that innovation and productivity is a critical focus. Nevertheless, the number of new molecular entities (NMEs) approved each year by FDA shows that industry has not been improving its output, despite progress in development and implementation of enabling technologies. Over the past 20 years there [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2010/01/11/rising-to-the-challenge-in-rd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>AIDS Drugs â€“ HIV</title>
		<link>http://www.bioscreening.net/2009/12/14/aids-drugs-%e2%80%93-hiv/</link>
		<comments>http://www.bioscreening.net/2009/12/14/aids-drugs-%e2%80%93-hiv/#comments</comments>
		<pubDate>Mon, 14 Dec 2009 21:19:58 +0000</pubDate>
		<dc:creator>Editor</dc:creator>
				<category><![CDATA[HIV Research]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Press Releases]]></category>

		<guid isPermaLink="false">http://www.bioscreening.net/2009/12/14/aids-drugs-%e2%80%93-hiv/</guid>
		<description><![CDATA[In the early 1980s, the human immunodeficiency virus (HIV) was identiÂ­fied as the etiologic agent of acquired immune deficiency syndrome (AIDS). More than 3 million people worldwide died from HIV/AIDS in 2003, according to a July 2004 United Nations report. During the same period, about 5 million people contracted the human immunodeficiency virus, bringing the [...]]]></description>
		<wfw:commentRss>http://www.bioscreening.net/2009/12/14/aids-drugs-%e2%80%93-hiv/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

